Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Evogene (NASDAQ: EVGN) received a Nasdaq notice for noncompliance with the $1.00 minimum bid price rule after its closing bid remained below $1.00 for 30 consecutive business days.

Rhea-AI Summary

Evogene (NASDAQ: EVGN) received a Nasdaq notice for noncompliance with the $1.00 minimum bid price rule after its closing bid remained below $1.00 for 30 consecutive business days.

The company has a 180-calendar-day cure period ending September 28, 2026 to regain compliance (10 consecutive business days at $1.00+). Trading will continue on Nasdaq during the cure period, and Evogene may consider options including a reverse stock split if needed.

Positive

• Trading continues on Nasdaq during cure period
• 180-day cure period through September 28, 2026 to regain compliance
• Eligibility for additional 180 days if other listing standards are met

Negative

• Closing bid price below $1.00 for 30 consecutive business days
• Risk of delisting if compliance not achieved by September 28, 2026
• Possible reverse stock split or other shareholder-impacting action may be considered

Argus Apr 6 session

-0.41% close to close Open Argus

Details

News Market Reaction – EVGN

In the Apr 6 session, EVGN declined 0.41%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights that EVGN’s Nasdaq closing bid has stayed below $1.00 for 30 consecutiv...

Analysis

This announcement highlights that EVGN’s Nasdaq closing bid has stayed below $1.00 for 30 consecutive business days, triggering a formal 180‑day cure period ending on September 28, 2026. Compliance requires at least 10 consecutive trading days with a bid of $1.00 or more, with a possible additional 180‑day extension. Investors may watch for any actions the company might take, such as a reverse stock split, alongside existing F‑3 warrant‑related resale capacity and recent going‑concern and restructuring disclosures.

Key Figures

Minimum bid price: $1.00 per share Noncompliance period: 30 consecutive business days Initial cure period: 180 calendar days +3 more

Minimum bid price

$1.00 per share

Nasdaq Rule 5550(a)(2) requirement

Noncompliance period

30 consecutive business days

Closing bid below $1.00 threshold

Initial cure period

180 calendar days

Time allowed to regain Nasdaq bid-price compliance

Compliance deadline

September 28, 2026

End of initial 180-day compliance window

Required compliant days

10 consecutive business days

Closing bid must be at least $1.00

Potential extension period

Up to 180 calendar days

Additional time if other Nasdaq criteria are met

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Subsidiary field trials

   24h Move

   +4.8%

   Casterra reported successful commercial castor field trials across 74 hectares in Brazil.

2. Mar 09

   Conference presentation

   24h Move

   -0.4%

   Company highlighted pharma discovery achievements and ChemPass AI at BIO-Europe Spring.

3. Mar 05

   Earnings results

   24h Move

   -6.2%

   Reported 2025 loss, inventory impairment, restructurings and reliance on warrant proceeds.

4. Feb 25

   CEO strategic letter

   24h Move

   +4.6%

   Outlined strategic refocus on ChemPass AI and divestiture of non-core assets.

5. Feb 19

   Earnings call schedule

   24h Move

   -5.6%

   Announced timing and access details for upcoming 2025 results release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

minimum bid price requirement, nasdaq capital market, reverse stock split

3 terms

minimum bid price requirement regulatory

"to regain compliance with the minimum bid price requirement."

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

nasdaq capital market regulatory

"listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement."

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

reverse stock split financial

"including potentially approving a reverse stock split, among other alternatives."

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, April 2, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for 30 consecutive business days.

 

The Nasdaq Stock Market Rules provide the Company a period of 180 calendar days to regain compliance. According to the Letter, the Company has until September 28, 2026, to regain compliance with the minimum bid price requirement. The Company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum period of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance from Nasdaq and this matter will be closed.

If the Company does not demonstrate compliance prior to the end of the 180-day period ending September 28, 2026, the Nasdaq staff will notify the Company that its ordinary shares will be subject to delisting.

However, the Company may then be eligible for additional time to regain compliance, of up to a further 180 calendar days, if it meets the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement. To be eligible, the Company will also need to provide further written notice of its intention to cure the deficiency during the second compliance period.

It is noted that Evogene's continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially approving a reverse stock split, among other alternatives.

The Letter from Nasdaq has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, as may be extended, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "EVGN". It is further noted that the Letter from Nasdaq has no bearing on Evogene's listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the ticker symbol "EVGN".

About Evogene Ltd.

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI^TM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. By integrating AI-driven molecular design with experimental validation, ChemPass AI™ enables the efficient discovery of differentiated small-molecule candidates with improved probability of development success. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com. 

Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene has utilized forward-looking statements in this press release when it discusses its ability to regain compliance with Nasdaq's Listing Qualification requirements including by potentially effecting a reverse stock split to regain compliance with the $1.00 minimum bid price requirement. Actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including, the ongoing  war between Israel and the United States against Iran and its sponsored terrorist group, Hezbollah, as well as those additional risk factors identified in Evogene's reports filed with the applicable securities authority. In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain activities, such as field-trials and pre-clinical studies, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections or assumptions.

Evogene Investor Relations Contact:

Email: ir@evogene.com

Tel: +972-8-9311901

Logo - https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/evogene-reports-receipt-of-nasdaq-minimum-bid-price-notification-302732572.html

SOURCE Evogene

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evogene (EVGN) receive from Nasdaq on April 2, 2026?

Evogene received a Nasdaq notice that its closing bid was below $1.00 for 30 consecutive business days. According to the company, Nasdaq Rule 5550(a)(2) noncompliance triggers a 180-day cure period ending September 28, 2026 to regain compliance.

How can EVGN regain compliance with Nasdaq's $1.00 minimum bid rule?

EVGN can regain compliance if the closing bid reaches at least $1.00 for ten consecutive business days. According to the company, achieving that 10-day $1.00+ threshold during the 180-day period results in written Nasdaq confirmation and closure of the matter.

Will Evogene shares continue trading on Nasdaq during the compliance period?

Yes, Evogene ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol EVGN during the cure period. According to the company, the Nasdaq letter has no immediate effect on listing or trading while the company attempts to regain compliance.

What happens if EVGN does not meet Nasdaq's minimum bid requirement by September 28, 2026?

If EVGN fails to demonstrate compliance by September 28, 2026, Nasdaq staff will notify the company that its shares will be subject to delisting. According to the company, it may then be eligible for an additional 180-day cure period if other listing standards are met.

What corrective actions might Evogene consider to cure the Nasdaq deficiency for EVGN?

Evogene may consider options including potentially approving a reverse stock split to raise the per‑share price. According to the company, the reverse stock split is among alternatives it intends to evaluate to regain compliance within the cure period.